3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
37
Liver Neoplasms
18
Neoplasm Metastasis
17
Colorectal Neoplasms
13
Cholangiocarcinoma
11
Pancreatic Neoplasms
9
Lung Neoplasms
8
Colonic Neoplasms
8
Breast Neoplasms
8
Barrett Esophagus
7
Recurrence
6
Carcinoma, Renal Cell
6
Carcinoma, Non-Small-Cell Lung
6
Thyroid Neoplasms
5
Rectal Neoplasms
5
Thyroid Nodule
4
Pain
4
Neoplasms
4
Kidney Neoplasms
4
Esophageal Neoplasms
4
Thyroid Cancer, Papillary
3
Biliary Tract Neoplasms
3
Agnosia
3
Thyroid Diseases
2
Prostatic Neoplasms
2
Leiomyoma
2
Hyperaldosteronism
2
Cancer Pain
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Interventions
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
4
napabucasin
3
Paclitaxel
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
entinostat
2
anlotinib
2
Taxes
2
Sunitinib
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Ocoxin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Carboplatin
2
sipuleucel-T
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
linifanib
1
lenvatinib
1
ixabepilone
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Glandular and Epithelial
×
Radiofrequency Ablation
×
Clear all
NCT02192671
2022-01-18
HR-HCC/PHT
Guangxi Medical University
Phase 3
Unknown
120 enrolled